|1.85 -0.23 (-11.06%)||12-08 16:00|
|Targets||6-month :||2.53||1-year :||2.96|
|Resists||First :||2.17||Second :||2.53|
|Supports||First :||1.66||Second :||1.35|
|MAs||MA(5) :||1.79||MA(20) :||1.58|
|MA(100) :||1.97||MA(250) :||2.26|
|MACD||MACD :||0||Signal :||-0.1|
|%K %D||K(14,3) :||80.4||D(3) :||83.9|
|52-week||High :||6.92||Low :||1.1|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PYXS ] has closed below upper band by 14.9%. Bollinger Bands are 54.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
|If tomorrow:||Open lower||Open higher|
|High:||2.11 - 2.12||2.12 - 2.13|
|Low:||1.77 - 1.78||1.78 - 1.79|
|Close:||1.83 - 1.85||1.85 - 1.86|
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||44 (M)|
|Shares Float||30 (M)|
|Held by Insiders||30.9 (%)|
|Held by Institutions||26.2 (%)|
|Shares Short||801 (K)|
|Shares Short P.Month||877 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||3.1|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||-30.9 %|
|Return on Equity (ttm)||-57.8 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-73 (M)|
|Levered Free Cash Flow||-47 (M)|
|Price to Book value||0.59|
|Price to Sales||0|
|Price to Cash Flow||-1.13|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|